Par Pharma branded business faces setback, say Zacks analysts

17 July 2011

US drugmaker Par Pharmaceuticals’ (NYSE: PRX) proprietary products division, Strativa Pharmaceuticals, recently faced a setback when MonoSol Rx and APR Applied Pharma Research announced that they will reacquire the US commercial rights to Zuplenz (ondansetron) from Strativa.

As a part of a licensing agreement with MonoSol Rx, Par Pharma had been marketing the product in the USA since October 2010, note analysts at Zacks Equity Research. Additionally, MonoSol Rx and APR Applied Pharma said that they are looking for a partner to commercialize Zuplenz in the USA.

Zuplenz, which was developed using MonoSol Rx's proprietary PharmFilm technology, is indicated for the prevention of postoperative nausea and vomiting (PONV), highly and moderately emetogenic cancer chemotherapy-induced nausea and vomiting (CINV), and radiotherapy-induced nausea and vomiting (RINV).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK